Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 7/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18860270 | 0.93 | CARM1 (0.48) | CARM1PRMT6KCNH2CACNA1IADRA1D | |
| SCHEMBL18838368 | 0.88 | CARM1 (0.46) | CARM1PRMT6KCNH2CACNA1IADRA1D | |
| SCHEMBL18860274 | 0.85 | KMT2A (0.43) | CARM1PRMT6CACNA1IMEN1KMT2A | |
| SCHEMBL18860337 | 0.85 | KCNH2 (0.59) | KCNH2CACNA1I | |
| SCHEMBL18860280 | 0.85 | KCNH2 (0.60) | KCNH2CACNA1IKMT2A | |
| SCHEMBL18860282 | 0.84 | HTR2A (0.54) | CARM1PRMT6KCNH2ADRA1AADRA1B | |
| SCHEMBL18838432 | 0.82 | CYP2D6 (0.43) | CARM1PRMT6ADRA1DADRA1AADRA1B | |
| SCHEMBL18860275 | 0.82 | DRD4 (0.54) | KCNH2MEN1KMT2AMCHR1 | |
| SCHEMBL18838388 | 0.79 | KCNH2 (0.46) | CARM1PRMT6KCNH2CACNA1IOPRM1 | |
| SCHEMBL18838334 | 0.78 | KDM4E (0.55) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | CARM1 4614/4885PRMT6 4254/4885KCNH2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.